Clindamycin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Clindamycin
- Clindamycin: From Bacterial Infections and Acne to Punctate Epithelial Keratoconjunctivitis
Clindamycin: From Bacterial Infections and Acne to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Clindamycin is a lincosamide antibiotic originally used for bacterial infections (streptococcal, staphylococcal, anaerobic and aspiration pneumonia), bacterial vaginosis and acne. The TxGNN model predicts it may be effective for punctate epithelial keratoconjunctivitis, but there are currently no clinical trials and no publications supporting this specific prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (streptococcal, staphylococcal, anaerobic), acne, bacterial vaginosis (the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 17 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Clindamycin is an antibacterial lincosamide. It inhibits bacterial protein synthesis by binding the 50S ribosomal subunit. Detailed mechanism-of-action data are not available in the data compiled for this report, so this description is based on general knowledge of the drug class.
Its established uses are against Gram-positive and anaerobic bacterial infections, acne and vaginal infections. Punctate epithelial keratoconjunctivitis is often viral or toxic/inflammatory in origin, so a direct antibacterial mechanism is not clearly relevant. The high score probably reflects network proximity to ocular surface infections rather than a validated mechanism.
For context, the other top-ranked predictions are mostly eye-surface conditions (exposure keratitis, neurotrophic keratopathy, epidemic keratoconjunctivitis and others). Only exposure keratitis has any related literature, and that literature concerns infectious keratitis, not clindamycin treatment of the predicted condition. The remaining predictions have no supporting evidence or a weak mechanistic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for punctate epithelial keratoconjunctivitis.
Singapore Market Information
Seventeen valid single-ingredient licences are listed. The five main ones are shown below. Approved indication text is not recorded for any of them.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN02170P | DALACIN C CAPSULE 150 mg | Capsule | Not recorded |
| SIN09496P | DALACIN C CAPSULE 300 mg | Capsule | Not recorded |
| SIN01502P | DALACIN C INJECTION 150 mg/ml | Injection | Not recorded |
| SIN09700P | DALACIN T TOPICAL GEL 1% | Gel | Not recorded |
| SIN07338P | DALACIN T LOTION 1% | Lotion | Not recorded |
Available forms across all licences are oral capsules, injections and solutions for injection, topical gels and lotions. No ophthalmic formulation is listed.
Safety Considerations
Contraindication signals from the knowledge graph (not label text): liver failure, Crohn disease, inflammatory bowel disease, ulcerative colitis, Clostridium difficile colitis, diarrhoeal disease, perinatal necrotizing enterocolitis, atopic and exfoliative dermatitis, sunburn, and vulvovaginal candidiasis.
Drug Interactions: 100 interactions were found. Those graded Moderate include balsalazide, clarithromycin, picosulfuric acid, attapulgite and kaolin. Others are of unknown severity (for example amphotericin B, aspirin, amoxicillin, vancomycin, morphine, metformin and several proton pump inhibitors).
Additional concern: Clindamycin is a recognized risk factor for C. difficile infection, consistent with the contraindication signals above.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials or literature behind it (L5), and the mechanistic link is weak because the condition is usually viral or inflammatory rather than bacterial. There is also no ophthalmic clindamycin product in Singapore.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- Detailed mechanism-of-action data
- Evidence that bacterial infection plays a role in punctate epithelial keratoconjunctivitis, or any clinical data on clindamycin in this condition
- An assessment of route and formulation feasibility, since only systemic and dermatological products are marketed
- A review of whether another prediction, such as exposure keratitis with secondary bacterial infection, is more tractable
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.